Miriam Potrony

List of Publications by Year
in descending order

41 papers	1,305 citations	516710 16 h-index	377865 34 g-index
42 all docs	42 docs citations	42 times ranked	2318 citing authors

#	Article	IF	Citations
1	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 2022, 28, 535-544.	30.7	158
2	Common genetic variants associated with melanoma risk or naevus count in patients with wildtype MC1R melanoma. British Journal of Dermatology, 2022, 187, 753-764.	1.5	6
3	Dermoscopy comparative approach for early diagnosis in familial melanoma: influence of MC1R genotype. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 403-410.	2.4	8
4	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers, 2021, 13, 2440.	3.7	6
5	Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update. Italian Journal of Dermatology and Venereology, 2021, 156, 322-330.	0.2	4
6	Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. Genetics in Medicine, 2021, 23, 2087-2095.	2.4	19
7	DNA Repair and Immune Response Pathways Are Deregulated in Melanocyte-Keratinocyte Co-cultures Derived From the Healthy Skin of Familial Melanoma Patients. Frontiers in Medicine, 2021, 8, 692341.	2.6	2
8	Influence of germline genetic variants on dermoscopic features of melanoma. Pigment Cell and Melanoma Research, 2021, 34, 618-628.	3.3	2
9	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. Journal of Medical Genetics, 2020, 57, 316-321.	3.2	33
10	Detection of cellâ€free circulating <scp> BRAF ^V </scp> ^{600E} by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. British Journal of Dermatology, 2020, 182, 382-389.	1.5	7
11	Inherited MC 1R variants in patients with melanoma are associated with better survival in women. British Journal of Dermatology, 2020, 182, 138-146.	1.5	10
12	Melanocortinâ€1 receptor (MC1R) genotypes do not correlate with size in two cohorts of mediumâ€toâ€giant congenital melanocytic nevi. Pigment Cell and Melanoma Research, 2020, 33, 685-694.	3.3	5
13	Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer. Hormones and Cancer, 2020, 11, 111-116.	4.9	12
14	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
15	Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. Journal of the American Academy of Dermatology, 2020, 83, 860-869.	1.2	5
16	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	5.6	16
17	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma. JAMA Dermatology, 2019, 155, 604.	4.1	34
18	<scp>POT</scp> 1 germline mutations but not <scp>TERT</scp> promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. British Journal of Dermatology, 2019, 181, 105-113.	1.5	37

#	Article	IF	Citations
19	Genome-wide linkage analysis in Spanish melanoma-prone families identifies a new familial melanoma susceptibility locus at 11q. European Journal of Human Genetics, 2018, 26, 1188-1193.	2.8	4
20	Melanocortin 1 receptor (<scp>MC</scp>1R) polymorphismsâ€™ influence on size and dermoscopic features of nevi. Pigment Cell and Melanoma Research, 2018, 31, 39-50.	3.3	28
21	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
22	Sex as a predictor of response to cancer immunotherapy. Lancet Oncology, The, 2018, 19, e375.	10.7	9
23	Genomic analysis and clinical management of adolescent cutaneous melanoma. Pigment Cell and Melanoma Research, 2017, 30, 307-316.	3.3	12
24	IRF4 rs12203592 functional variant and melanoma survival. International Journal of Cancer, 2017, 140, 1845-1849.	5.1	11
25	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
26	The p. R151C Polymorphism in MC1R Gene Modifies the Age of Onset in Spanish Huntingtonâ€™s Disease Patients. Molecular Neurobiology, 2017, 54, 3906-3910.	4.0	5
27	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. International Journal of Cancer, 2016, 139, 1297-1302.	5.1	14
28	Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1733-1738.	2.3	2
29	Association Between Confocal Morphologic Classification and Clinical Phenotypes of Multiple Primary and Familial Melanomas. JAMA Dermatology, 2016, 152, 1099.	4.1	13
30	Genetic susceptibility to cutaneous melanoma in southern Switzerland: role ofCDKN2A,MC1RandMITF. British Journal of Dermatology, 2016, 175, 1030-1037.	1.5	17
31	Reply. Annals of Neurology, 2016, 79, 161-163.	5.3	3
32	Reply. Annals of Neurology, 2016, 79, 868-868.	5.3	0
33	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: AÂPooled Analysis from the M-Skip Project. Journal of Investigative Dermatology, 2016, 136, 1914-1917.	0.7	16
34	Prevalence ofMITFp.E318K in Patients With Melanoma Independent of the Presence ofCDKN2ACausative Mutations. JAMA Dermatology, 2016, 152, 405.	4.1	41
35	Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. Genetics in Medicine, 2016, 18, 727-736.	2.4	31
36	Reply. Annals of Neurology, 2015, 78, 153-154.	5.3	1

#	Article	IF	Citations
37	The <scp>MC1R</scp> melanoma risk variant p.<scp>R160W</scp> is associated with <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 77, 889-894.	5.3	52
38	Update in genetic susceptibility in melanoma. Annals of Translational Medicine, 2015, 3, 210.	1.7	100
39	Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling. Journal of the American Academy of Dermatology, 2014, 71, 888-895.	1.2	52
40	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	204
41	Role of <scp>CPI</scp>â€17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a filmâ€forming medical device containing photolyase and <scp>UV</scp> filters. Experimental Dermatology, 2013, 22, 494-496.	2.9	19